A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
PSA response following cytarabine treatment
50% decline in PSA from baseline, confirmed by a second measurement ≥3 weeks later
No
Anthony Joshua, MD
Principal Investigator
University Health Network, Toronto
Canada: Health Canada
SLAP41206
NCT00480090
April 2007
July 2011
Name | Location |
---|